Eloralintide

1 Identity

Synthetic lipidated amylin-receptor agonist, 37 residues, C-terminally amidated, macrocyclized by a Cys2-Cys7 methylene (thioether) bridge rather than a disulfide, with a Lys26 gamma-Glu-gamma-Glu-C20-diacid albumin-binding side chain. Contains four non-proteinogenic residues: Orn11, alpha-Me-Phe15, N-Me-Asn22, and an N-terminal gamma-Glu. No trade name and no approval; three independent sellers list it as "Eloralintide peptide 1MG/10MG vial".

Sequence

A vendor-concordant sequence circulates across four catalog suppliers, carrying a Cys2-Cys7 methylene bridge and the Lys26 lipidation described above. This company does not adopt it. Neither the who INN monograph nor the originator's published structure is publicly available, and four vendors agreeing is one upstream source repeated four times, not four confirmations. The sequence stays unverified pending the INN monograph.

Molecular formula

C201H319N49O65S2, as circulated by four reagent catalogs. Unverified: one upstream source, with no primary-literature and no pharmacopoeial confirmation.

Average mass

4526.10 Da average, as circulated by the same four vendor sources, and equally unverified. No mass is calculated from that formula: a precise figure derived from an unverified formula carries no more authority than the formula it came from, and printing it would launder the uncertainty.

Monoisotopic mass

Not available. No published monoisotopic value was located.

Salt / variant note

Cagrilintide, C194H312N54O59S2, 4409.01 Da, CAS 1415456-99-3, already in the catalog, is also a 37-mer C20-diacid-lipidated amylin analog, carrying a Cys3-Cys8 bridge. Roughly 117 Da separates the two and their chromatographic behavior is nearly identical. Also petrelintide; pramlintide, C171H267N51O53S2, approximately 3949.4 Da; davalintide; native human amylin; and any vial labeled only "amylin analog", which in this market can be any of them.

2 Class & testing panel

Form

Single article

Testing panel

Special-class panel — panel definition

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Program evidence is real and recent: Phase 2 results published in The Lancet in 2025, and an originator press release of 6 November 2025. Structural evidence is weak: no INN monograph, no primary structure figure, and a formula circulating from one upstream source. This company does not describe what the article does; it records that the identity data available to a buyer in this channel is thinner than the clinical data.

4 Storage & specification

Storage

Not assigned. The article is not offered.

Shelf life

Not assigned. The article is not offered.